Last checked at 
(Alliance News) - PureTech Health PLC on Wednesday said its affiliate Akili reported top-line results of its multi-site open-label study to evaluate the effects of AKL-T01 in children with attention deficit hyperactivity disorder.
The FTSE 250-listed biotechnology investor said the study achieved its predefined primary efficacy outcome, demonstrating a statistically significant improvement in the attention deficit hyperactivity disorder impairment rating scale from baseline after one month of treatment.
"We are pleased with these new results as they provide additional support for AKL-T01 in paediatric attention deficit hyperactivity disorder - both as a monotherapy and in combination with stimulant medications," said PureTech Chief Innovation Officer Eric Elenko.
PureTech shares were trading 0.7% higher in London on Wednesday at 274.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
